Interim Data from a Randomized, Placebo Controlled, Phase 1 Study of Aln-AS1, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria
Year: 2016
Type: conference-abstract
Study design: Clinical Trial
Source: Blood
Institutions: Karolinska University Hospital, Karolinska Institutet, Icahn School of Medicine at Mount Sinai, The University of Texas Medical Branch at Galveston, University of Alabama, University of Alabama at Birmingham, University of California, San Francisco, University of Utah, University of Connecticut, UConn Health, Alnylam Pharmaceuticals (United States), King's College Hospital
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2610698758
